Serotonergic Drugs for Depression and Beyond
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
The current generation of antidepressant drugs acts predominantly by targeting the serotonin transporter (SERT). The original trend to do this selectively (e.g., with SSRIs or selective serotonin reuptake inhibitors) has given way to combining various additional pharmacologic mechanisms with SERT inhibition, including dual actions by single drugs (e.g., SNRIs or serotonin norepinephrine reuptake inhibitors), or by augmenting SSRIs with a second drug of a different mechanism (e.g., bupropion with dopamine and norepinephrine reuptake inhibition; trazodone with 5HT2A antagonism; mirtazapine with 5HT2A/5HT2C/5HT3/alpha2 antagonism; buspirone or some atypical antipsychotics with 5HT1A partial agonism; other atypical antipsychotics with 5HT2C/5HT7 antagonism and other mechanisms). Novel drugs in development include those that combine multiple simultaneous pharmacologic mechanisms in addition to SERT inhibition within the same molecule, such as vilazodone (combining 5HT1A partial agonism with SERT inhibition), triple reuptake inhibitors (combining norepinephrine and dopamine reuptake inhibition with SERT inhibition), and vortioxetine, a multimodal antidepressant combining actions at the G protein receptor mode (5HT1A and 5HT1B partial agonism and 5HT7 antagonism), at the ion channel mode (5HT3 antagonism) as well as the neurotransmitter transporter mode (SERT inhibition). These various strategies that build upon SERT inhibition provide promise for novel therapeutic approaches to depression, including the possibility of targeting residual symptoms not well treated by SERT inhibition alone, and reducing side effects, such as sexual dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission
Alex, K. D., & Pehek, E. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.004 · Cited by 658
Effects of SSRIs on Sexual Function: A Critical Review
Rosen, R. C., Lane, R. M., & Menza, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00013 · Cited by 650
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Cobos, E., Entrena, J., Nieto, F., Cendan, C., & Pozo, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386113 · Cited by 376
Haria, M., Fitton, A., & McTavish, D. (1994) · Drugs & Aging · doi:10.2165/00002512-199404040-00006 · Cited by 332
Mørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sánchez, C., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189068 · Cited by 271
Dwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00178.x · Cited by 259
Häuser, W., Wolfe, F., Tölle, T., Üçeyler, N., & Sommer, C. (2012) · CNS Drugs · doi:10.2165/11598970-000000000-00000 · Cited by 193
Stahl, S. M. (2003) · PubMed · Cited by 181
Regulation of the dopamine transporter: Aspects relevant to psychostimulant drugs of abuse
Schmitt, K. C., & Reith, M. E. A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05148.x · Cited by 180
Blockage of 5HT2Cserotonin receptors by fluoxetine (Prozac)
Ni, Y. G., & Miledi, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2036 · Cited by 177
Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy
Mnie‐Filali, O., Faure, C., Lambás‐Señas, L., Mansari, M. E., Belblidia, H., Gondard, E., Etiévant, A., Scarna, H., Didier, A., Bérod, A., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.13 · Cited by 169
Pehrson, A. L., Cremers, T., Bétry, C., van der Hart, M. G. C., Jørgensen, L., Madsen, M., Haddjeri, N., Ebert, B., & Sanchez, C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.006 · Cited by 155
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Shah, N. R., Jones, J. B., Aperi, J., Shemtov, R., Karne, A., & Borenstein, J. (2008) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31816fd73b · Cited by 143
Moret, C., & Briley, M. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00581-1 · Cited by 136
Jain, R., Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Thase, M. E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000727 · Cited by 132
Lockhart, P., & Guthrie, B. (2011) · British Journal of General Practice · doi:10.3399/bjgp11x593848 · Cited by 123
Bupropion occupancy of the dopamine transporter is low during clinical treatment
Meyer, J. H., Goulding, V. S., Wilson, A. A., Hussey, D., Christensen, B. K., & Houle, S. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1166-3 · Cited by 122
Review: The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target?
Rajkumar, R., & Mahesh, R. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109348161 · Cited by 116
Carvalho, A. F., Cavalcante, J. L., Castelo, M. S., & Lima, M. C. O. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00846.x · Cited by 110
Preclinical and Clinical Pharmacology of DOV 216,303, a “Triple” Reuptake Inhibitor
Skolnick, P., Krieter, P. A., Tizzano, J. P., Basile, A. S., Popik, P., Czobor, P., & LIPPA, A. S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00123.x · Cited by 107
Zhong, H., Haddjeri, N., & Sánchez, C. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2463-5 · Cited by 105
Prins, J., Olivier, B., & Korte, S. M. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.594039 · Cited by 97
Guiard, B., Mansari, M., & Blier, P. (2009) · Current Drug Targets · doi:10.2174/138945009789735156 · Cited by 90
Quetiapine: A Review of its Use in the Management of Bipolar Depression
Sanford, M., & Keating, G. M. (2012) · CNS Drugs · doi:10.2165/11203840-000000000-00000 · Cited by 88
Fowler, J. S., Volkow, N. D., Wang, G., Gatley, S. J., & Logan, J. (2001) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(01)00211-6 · Cited by 83
Tran, P., Skolnick, P., Czobor, P., Huang, N. Y., Bradshaw, M., McKinney, A., & Fava, M. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.09.003 · Cited by 81
Second-generation antipsychotics in major depressive disorder: update and clinical perspective
Chen, J., Gao, K., & Kemp, D. E. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283413505 · Cited by 80
Bartoszyk, G. D., Hegenbart, R., & Ziegler, H. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00999-5 · Cited by 78
Treatments for diabetic neuropathy
Bril, V. (2012) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2012.00391.x · Cited by 78
Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
Baldwin, D. S., Hansen, T., & Florea, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.725035 · Cited by 71
Rabiner, E. A., Gunn, R. N., Wilkins, M. R., Sargent, P. A., Mocaër, E., Sedman, E., Cowen, P. J., & Grasby, P. M. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00120-7 · Cited by 70
Presynaptic autoreceptors regulating transmitter release
Langer, S. Z. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.031 · Cited by 69
Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression
Khan, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903286396 · Cited by 66
Dawson, L. A., & Nguyen, H. Q. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01580-x · Cited by 63
Schwartz, T. L., Siddiqui, U. A., & Stahl, S. M. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311409486 · Cited by 55
The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder
Moreira, R. (2011) · Clinical Drug Investigation · doi:10.2165/1159616-s0-000000000-00000 · Cited by 55
A Comparison of the Physicochemical and Biological Properties of Mirtazapine and Mianserin
Kelder, J., Funke, C. W., de Boer, T., Delbressine, L. P. C., Leysen, D. C., & Nickolson, V. J. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06814.x · Cited by 54
Stahl, S. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0201 · Cited by 49
Dose-Response Relationship With Venlafaxine
KELSEY, J. E. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606002-00005 · Cited by 48
Review of the use of mirtazapine in the treatment of depression
Benjamin, S., & Doraiswamy, P. M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.585459 · Cited by 46
Bech, P., Fava, M., Trivedi, M. H., Wisniewski, S. R., & Rush, A. J. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01791.x · Cited by 46
Star-D: lessons learned and future implications
Rush, A. J. (2011) · Depression and Anxiety · doi:10.1002/da.20841 · Cited by 43
Asenapine: A Clinical Review of a Second-Generation Antipsychotic
Stoner, S. C., & Pace, H. A. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.03.002 · Cited by 42
Citrome, L., & Weiss–Citrome, A. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2521 · Cited by 41
Stahl, S. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0101 · Cited by 41
Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action.
Potter, W. Z. (1996) · PubMed · Cited by 40
Milnacipran: a unique antidepressant?
Briley, M. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s11777 · Cited by 38
de Paulis, T. (2007) · PubMed · Cited by 35
Sanford, M. (2011) · CNS Drugs · doi:10.2165/11207280-000000000-00000 · Cited by 32
Quetiapine: novel uses in the treatment of depressive and anxiety disorders
Ravindran, A. V., Al‐Subaie, A., & Abraham, G. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.515586 · Cited by 30
Pangallo, B. A., Dellva, M. A., D’Souza, D. N., Essink, B., Russell, J., & Goldberger, C. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.03.014 · Cited by 29
Schwartz, T. L., & Singh, M. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s20683 · Cited by 27
The Role of Venlafaxine in the Treatment of Obsessive—Compulsive Disorder
Phelps, N. J., & Cates, M. E. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e362 · Cited by 27
Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility
Dodd, S., & Berk, M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.9.1299 · Cited by 22
Kim, J. E., Yoon, S. J., Kim, J., Jung, J. Y., Jeong, H., Cho, H., Shin, E.-K., Lyoo, I. K., & Kim, T. S. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02624.x · Cited by 22
Duloxetine in the Treatment of Depression: An Overview
Monteleone, F., Caputo, M., Tecce, M. F., & Capasso, A. (2011) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152411798047807 · Cited by 20
Desvenlafaxine in the treatment of major depressive disorder
Kennedy, S. H. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3360 · Cited by 19
Cited by
Hannibal, K. E., & Bishop, M. D. (2014) · Physical Therapy · doi:10.2522/ptj.20130597 · Cited by 729
Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions
Scotton, W. J., Hill, L. J., Williams, A. C., & Barnes, N. M. (2019) · International Journal of Tryptophan Research · doi:10.1177/1178646919873925 · Cited by 267
Pehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161
Fagiolini, A., Florea, I., Loft, H., & Christensen, M. C. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.106 · Cited by 127
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Metadata
- Authors
- M. Stahl, S., Lee-Zimmerman, C., Cartwright, S., & Ann Morrissette, D.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-04-01
- Volume
- 14
- Issue
- 5
- Pages
- 578-585
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2102298517
- Cited by
- 272
- References
- 61
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.